Difference between revisions of "NF-kappa-B inhibitor alpha"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 49: | Line 49: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:49, 10 March 2015
| NF-kappa-B inhibitor alpha | |
|---|---|
| Substrate peptide name | NF-kappa-B inhibitor alpha |
| Synonyms | I-kappa-B-alpha |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytosol |
| Swissprot ID | P25963 |
| Reactive glutamines | Q266, Q267, Q313 |
| Reactive lysines | K21, K22, K177 |
| Substrate sequence | PRDGLKKERLLD
LHSILKATNYN PSTRIQQQLGQL DCVFGGQRLTL |
| Structure | 1IKN |
| Surface accessibility | ASAView pdf |
| Disorder prediction | IUPred |
| Reference | PMID:16987813 |
| Notes | |
